CL2013003497A1 - Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. - Google Patents
Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.Info
- Publication number
- CL2013003497A1 CL2013003497A1 CL2013003497A CL2013003497A CL2013003497A1 CL 2013003497 A1 CL2013003497 A1 CL 2013003497A1 CL 2013003497 A CL2013003497 A CL 2013003497A CL 2013003497 A CL2013003497 A CL 2013003497A CL 2013003497 A1 CL2013003497 A1 CL 2013003497A1
- Authority
- CL
- Chile
- Prior art keywords
- umeclidinium
- mcg
- inhaler
- inflammatory
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494600P | 2011-06-08 | 2011-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003497A1 true CL2013003497A1 (es) | 2014-07-04 |
Family
ID=46201674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003497A CL2013003497A1 (es) | 2011-06-08 | 2013-12-05 | Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140113888A1 (es) |
| EP (1) | EP2717868A1 (es) |
| JP (1) | JP2014516062A (es) |
| KR (1) | KR20140041699A (es) |
| CN (1) | CN103582477A (es) |
| AU (1) | AU2012266541A1 (es) |
| BR (1) | BR112013031572A2 (es) |
| CA (1) | CA2838030A1 (es) |
| CL (1) | CL2013003497A1 (es) |
| CO (1) | CO6821951A2 (es) |
| CR (1) | CR20130643A (es) |
| DO (1) | DOP2013000290A (es) |
| EA (1) | EA201391618A1 (es) |
| IL (1) | IL229633A0 (es) |
| MA (1) | MA35406B1 (es) |
| MX (1) | MX2013014399A (es) |
| PE (1) | PE20141048A1 (es) |
| SG (1) | SG195262A1 (es) |
| WO (1) | WO2012168161A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| CN107254058A (zh) | 2011-12-28 | 2017-10-17 | 旭化成株式会社 | 氧化还原液流二次电池和氧化还原液流二次电池用电解质膜 |
| JP6267685B2 (ja) | 2012-04-13 | 2018-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 集合粒子 |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| ES2959699T3 (es) | 2014-05-28 | 2024-02-27 | Glaxosmithkline Ip Dev Ltd | Furoato de fluticasona en el tratamiento de la EPOC |
| WO2015193631A1 (en) | 2014-06-18 | 2015-12-23 | Cipla Limited | Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent |
| CN107200734B (zh) * | 2016-03-18 | 2019-12-24 | 益方生物科技（上海）有限公司 | 奎宁环衍生物及其制备方法和用途 |
| TR201712424A2 (tr) * | 2017-08-21 | 2019-03-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Kuru toz i̇nhalasyon bi̇leşi̇mleri̇ |
| US20210353650A1 (en) * | 2020-05-18 | 2021-11-18 | Cai Gu Huang | Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| ES2122261T3 (es) | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester. |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| AR032361A1 (es) | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| SE527191C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av tiotropium och fluticason |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| PE20060826A1 (es) * | 2004-12-06 | 2006-10-08 | Smithkline Beecham Corp | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| EP2197444A1 (en) * | 2007-09-12 | 2010-06-23 | Glaxo Group Limited | Novel combination of therapeutic agents |
| DK2400950T3 (da) * | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
-
2012
- 2012-06-01 US US14/124,276 patent/US20140113888A1/en not_active Abandoned
- 2012-06-01 BR BR112013031572A patent/BR112013031572A2/pt not_active IP Right Cessation
- 2012-06-01 SG SG2013089123A patent/SG195262A1/en unknown
- 2012-06-01 AU AU2012266541A patent/AU2012266541A1/en not_active Abandoned
- 2012-06-01 WO PCT/EP2012/060444 patent/WO2012168161A1/en active Application Filing
- 2012-06-01 MX MX2013014399A patent/MX2013014399A/es unknown
- 2012-06-01 CA CA2838030A patent/CA2838030A1/en not_active Abandoned
- 2012-06-01 JP JP2014514008A patent/JP2014516062A/ja active Pending
- 2012-06-01 KR KR1020147000491A patent/KR20140041699A/ko not_active Application Discontinuation
- 2012-06-01 PE PE2013002753A patent/PE20141048A1/es not_active Application Discontinuation
- 2012-06-01 EA EA201391618A patent/EA201391618A1/ru unknown
- 2012-06-01 CN CN201280027664.6A patent/CN103582477A/zh active Pending
- 2012-06-01 EP EP12725047.0A patent/EP2717868A1/en not_active Withdrawn
-
2013
- 2013-11-26 IL IL229633A patent/IL229633A0/en unknown
- 2013-12-05 CL CL2013003497A patent/CL2013003497A1/es unknown
- 2013-12-06 DO DO2013000290A patent/DOP2013000290A/es unknown
- 2013-12-09 CO CO13287946A patent/CO6821951A2/es not_active Application Discontinuation
- 2013-12-09 CR CR20130643A patent/CR20130643A/es unknown
-
2014
- 2014-01-03 MA MA36643A patent/MA35406B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2838030A1 (en) | 2012-12-13 |
| CO6821951A2 (es) | 2013-12-31 |
| JP2014516062A (ja) | 2014-07-07 |
| IL229633A0 (en) | 2014-01-30 |
| KR20140041699A (ko) | 2014-04-04 |
| MX2013014399A (es) | 2014-03-21 |
| NZ618166A (en) | 2016-01-29 |
| EP2717868A1 (en) | 2014-04-16 |
| EA201391618A1 (ru) | 2014-05-30 |
| PE20141048A1 (es) | 2014-09-08 |
| SG195262A1 (en) | 2013-12-30 |
| US20140113888A1 (en) | 2014-04-24 |
| CR20130643A (es) | 2014-02-04 |
| AU2012266541A1 (en) | 2014-01-09 |
| DOP2013000290A (es) | 2014-03-16 |
| WO2012168161A1 (en) | 2012-12-13 |
| CN103582477A (zh) | 2014-02-12 |
| MA35406B1 (fr) | 2014-09-01 |
| BR112013031572A2 (pt) | 2017-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003497A1 (es) | Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| BR112016018365A2 (pt) | Formulação farmacêutica aerossol, na forma de um pó seco para distribuição pulmonar, seus usos, forma de dosagem unitária, embalagem ou kit farmacêutico, e dispositivo de distribuição de pó seco | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| AR100368A1 (es) | Tratamiento de trastornos respiratorios | |
| DOP2014000269A (es) | Nueva dosificación y formulación | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| CL2014001905A1 (es) | Dispositivo de inhalacion para farmacos en polvo a ser recibidos por un paciente mediante una corriente de aire producida por inhalacion que comprende un deposito para polvo, un medio de medicion de la dosis de polvo, un mecanismo de transporte para mover dicho medio de medicion, y un dispositivo de activacion para el uso manual por parte del paciente. | |
| CL2013003556A1 (es) | Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CL2016000724A1 (es) | Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda. | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| UY35900A (es) | Nueva dosificación y formulación |